Back to News
Market Impact: 0.25
Shennon Biotechnologies Raises $12M in Financing, Appoints Cyril Konto, M.D., as Chief Executive Officer and Unveils Precision Immunotherapy Pipeline
Source: Business Wire
Healthcare & BiotechPrivate Markets & VentureManagement & GovernanceProduct Launches
Shennon Biotechnologies raised $12 million in financing, appointed Cyril Konto, M.D., as chief executive officer, and unveiled a precision immunotherapy pipeline. The funding and leadership appointment support development of the company’s immunotherapy programs, though no clinical, valuation, or commercialization details were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- Google's Gemini 4 Carbon looks like a diamond in the rough
- FedEx beats expectations, raises outlook in first report since calendar adjustment
- Samsung Electronics third-quarter profit in line with estimates amid rising demand for AI memory chips
- Fed chairman talks tough on inflation — plus, what's behind Micron's big rally
- Bausch Health raises 2026 outlook as third-quarter adjusted earnings surge 53%
- Investors Eye AI Payoff in Microsoft, Alphabet Earnings